臨床研究等提出・公開システム

Exploratory clinical study on the smartphone application for type 2 diabetes

Exploratory clinical study on the smartphone application for type 2 diabetes

Eiji Arita

Terumo Corporation

1500 Inokuchi, Nakai-machi, Ashigarakami-gun, Kanagawa, 259-0151 JAPAN

eiji_arita@terumo.co.jp

Naoki Toyoshima

Terumo Corporation

1500 Inokuchi, Nakai-machi, Ashigarakami-gun, Kanagawa, 259-0151 JAPAN

+81-465-81-4256

naoki_toyoshima@terumo.co.jp

Complete

May. 06, 2022

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

health services research

All of the following criteria must be met in order to participate in this study.
1) Patients who are visiting "Okamoto Clinic" or "Tomonaga Clinic" or "Mirai Clinic" ("the trial institutions") and who have obtained written informed consent.
2) Patients aged 20 to 65 years at the time of obtaining consent.
3) Patients scheduled to visit the trial institutions once a month.
4) Patients who, at the time of obtaining consent, have been diagnosed with type 2 diabetes for at least 12 weeks.
5) Patients with HbA1c value of 7.0% to 9.0% or less at the time of obtaining consent. (If HbA1c at the time of obtaining consent is not available, it is permitted to use HbA1c within 3 months from the time of obtaining consent.)
6) Patients who own iPhone and have been using it continuously for 12 weeks or more. (It is deemed that patients are using iPhone continuously, if they use it more than 4 days a week.)
7) Patients deemed by the investigator to be able to use the diabetes management program DRM01 ("the app").

Subjects were excluded based on 16 criteria:
1) Type 1 diabetes.
2) Secondary diabetes.
3) Patients receiving or planning to start intensive insulin therapy.
4) Patients with renal impairment. (eGFR less than 45 mL/min/1.73m2 or urinary microalbumin more than 300 mg/gCre)
5) Patients undergoing or planning to start hemodialysis.
6) Patients who have been diagnosed with dementia or are being treated for dementia.
7) Patients with experience requiring third-party intervention to treat hypoglycemia.
8) Patients with or need to have any exercise or dietary restrictions due to diseases other than diabetes.
9) Patients who have liver or cardiovascular diseases and are judged by the doctor to be difficult to participate in this study.
10) Patients with malignant tumors.
11) Patients with serious infections.
12) Patients who are dependent on alcohol or drugs, or have unstable psychiatric disorders and are deemed by the investigator to be inappropriate for this study.
13) Patients scheduled to be hospitalized or undergo surgery during the study period.
14) Patients who are pregnant, may be pregnant, or wish to be pregnant. (women only)
15) Patients who participated in other clinical trials in the 4 weeks prior to the consent of this study.
16) Patients deemed by the investigator to be inappropriate for this study.

Both

Type 2 diabetes

In this study, the subjects are required to use the app daily for 12 weeks in principle. It is possible that the use of the app have a slight impact on medical care and change the doctor's response slightly. And behavior change could occur in the patient's self-management.

D003924

Application usage rate and usage rate by recorded item

Monthly changes in app usage
Questionnaire survey
Relationship between app input data and app usage rate

+81-3-5841-0818

Mar. 25, 2022

+81-465-81-4115

Mar. 25, 2022

No

none